Oncopeptides AB

Equities

ONCO

SE0009414576

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:56 2024-04-24 am EDT			5-day change	1st Jan Change
3.22 ^SEK	+2.06%		-27.96%	-57.96%

Apr. 15	Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain	CI
Apr. 04	Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024	CI

Oncopeptides AB Announces Board Appointments

May 17, 2018 at 12:30 pm EDT

Oncopeptides AB (publ) at its annual general meeting held on May 17, 2018 elected Brian Stuglik and Per Wold-Olsen as new board members. Per Wold -Olsen was also elected as chairman of the board of directors.

Latest news about Oncopeptides AB

Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain	Apr. 15	CI
Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024	Apr. 04	CI
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa	Mar. 27	CI
Oncopeptides Plans SEK300 Million Rights Issue to Support Multiple Myeloma Drug Commercialization	Mar. 13	MT
Transcript : Oncopeptides AB, Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Oncopeptides AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Oncopeptides AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Global markets live: Domino's Pizza, Walt Disney, Broadcom, Ryanair, Exxon Mobil, Goldman Sachs...	Feb. 26
FDA Officially Withdraws Approval of Oncopeptides Pepaxto	Feb. 23	DJ
Oncopeptides to Assess US FDA's Withdrawal of Blood Cancer Drug Approval	Feb. 23	MT
Spanish Authority Gives Positive Recommendation for Pricing of Oncopeptides' Blood Cancer Drug	Feb. 23	MT
Oncopeptides Receives Positive Recommendation for Pepaxti by Spanish Pricing Authority	Feb. 23	CI
Oncopeptides Extends Exclusive Rights to Cancer Drug Until 2037	Feb. 15	MT
Oncopeptides Announces European Commission Decides to Formally Approve its Application to EMA for Extended Indication for Pepaxti into Earlier Lines	Dec. 15	CI
Oncopeptides' New CFO Takes Office	Nov. 13	MT
Oncopeptides Selects to Present Additional Data from Ocean Study	Nov. 13	CI
Oncopeptides AB Appoints Henrik Bergentoft as Chief Financial Officer	Nov. 13	CI
Transcript : Oncopeptides AB, Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
Oncopeptides AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Oncopeptides AB Announces the Nomination Committee	23-10-20	CI
Oncopeptides AB Announces Its Decision to Adopt the Application Process to Allow Pertide Access to Patients with Relapsed, Refractory Multiple Myeloma	23-09-28	CI
Oncopeptides AB(OM:ONCO) dropped from S&P Global BMI Index	23-09-18	CI
Oncopeptides Secures EU Committee Backing for Expanded Indication of Multiple Myeloma Therapy; Shares Surge	23-09-14	MT
Oncopeptides AB Announces Positive Opinion on Type II Variation to Extend the Therapeutic Indication of Pepaxti Based on Ocean Trial Results	23-09-14	CI
Oncopeptides AB Publishes Two Articles with Results from Anchor and LIGHTHOUSE Studies in Haematologica	23-09-04	CI

Chart Oncopeptides AB

Duration

Period

More charts

Company Profile

Oncopeptides AB is a Sweden-based biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The Companyâs lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.

Sector

Biotechnology & Medical Research

Calendar

2024-05-03 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Oncopeptides AB

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ONCOPEPTIDES AB	-57.96%	28.79M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	105B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.5B
ARGENX SE	+1.86%	22.19B
BIONTECH SE	-16.53%	21.33B
GENMAB A/S	-8.49%	18.68B
WUXI APPTEC CO., LTD.	-42.33%	16.6B
BEIGENE, LTD.	-20.09%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	14.09B
SAREPTA THERAPEUTICS, INC.	+28.85%	10.99B

Bio Therapeutic Drugs